Freedom of information requests

Dabrafenib + Trametinib for cancer treatments

Questions

1. Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:
a) Metastatic Melanoma 
b) Adjuvant Melanoma 
c) BRAF mutated Lung Cancer 

Response

Please note – this response covers four hospitals.
QE = Queen Elizabeth Hospital Birmingham
HGS = Heartlands, Good Hope and Solihull Hospitals

QE:

a) Metastatic Melanoma 1
b) Adjuvant Melanoma 0
c) BRAF mutated Lung Cancer 0

HGS data taken from ChemoPMR:

a) Metastatic Melanoma - 0
b) Adjuvant Melanoma - 0
c) BRAF mutated Lung Cancer – only 1 patient listed for NSCLC – not specified any further on ChemoPMR